Flowable Hemostats Market Business overview 2022, and Forecast to 2028
The global Flowable hemostats market size is expected to reach US$ 1,422.78 million by 2028, registering a CAGR of 6.9% from 2022 to 2028, according to a new research study conducted by The Insight Partners.
Flowable hemostats have flowable consistency and contain a porcine or bovine gelatin matrix. It may add topical thrombin. When an application is needed on a difficult-reach surface or in a wet field flowable hemostats are helpful. The product can be used for all surgical procedures except ophthalmic. Major factors driving the market growth include an increasing number of injuries and surgical procedures, and a rising geriatric population. However, the shortage of skilled professionals and poor reimbursement policies are likely to hamper the market growth.
The report highlights the major factors driving the market and prominent players with their developments. The market is primarily driven by the increasing number of injuries and surgical procedures and the rising geriatric population. However, poor reimbursement policies and a shortage of skilled professionals are hampering the growth of the global flowable hemostats market.
Flowable hemostats market is a boosting industry Know why https://www.theinsightpartners.com/sample/TIPRE00015216/
The flowable hemostats market is majorly comprised of top players Baxter International Inc; Teleflex Incorporated; Johnson & Johnson; Biom'up; Pfizer Inc.; Aegis Lifesciences; 3-D Matrix Medical Technology; among others. The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company's growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Flowable hemostatic agents are thick, flowable consistency products comprising two chief components, active and passive, which convert fibrinogen to fibrin at the site of bleeding. The passive component is either bovine or porcine gelatin, while the active component is thrombin. Thrombin addition to gelatin may not be required in some instances. Flowable hemostats are considered highly efficacious in achieving hemostasis due to the combined effect of these constituents.
Based on material, the global flowable hemostats market is bifurcated into bovine gelatin and porcine gelatin. The bovine segment holds a larger market share in 2022 and is anticipated to register a higher CAGR of 7.1% in the market during the forecast period. The market for the bovine gelatin segment is growing due to the rise in the prevalence of chronic cardiac diseases. Bovine gelatin is a protein-based product produced by partial hydrolysis of collagen.
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1–646–491–9876
Comments
Post a Comment